Global Gene Therapy Market Forecast to 2020: Adenovirus Vector: Gaining Popularity for Oncology Gene Therapy - Research and Markets
DUBLIN, May 12, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering.
According to the new research report Global Gene Therapy Market Forecast to 2020, a major focus has been on the ongoing clinical trials for the development of innovative products using different vectors.
One of the majorly used vectors was adenoviral vector. Adenoviral vectors consist of several features that make them well suited for this application. They are highly effective in gene therapy due to their ability to efficiently transduce in both dividing as well as non-dividing cells.
Adenoviral vector is the most used vector in oncology application. This vector system has shown real promise in treating cancer and indeed the first gene therapy product (Gendicine) to be licensed is an adenovirus to treat cancer. According to the Journal of Gene Medicine, July 2015, 506 trials have been reported using adenoviral vector. Currently, adenoviral vectors are being used in suicide gene therapy, gene-based immunotherapy, gene replacement strategies, and in approaches that combine gene therapy with chemotherapy. In addition, treatment with replication competent adenovirus vectors is also showing promising results in clinical trials
Some of the key highlights of the report include the following:
- Mergers and Acquisitions advancing gene therapy research and development
- US showing dynamic research and development for gene therapy.
- Growing clinical trials for gene therapy worldwide.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Gene Therapy - An Introduction
3.1 Classification of Gene Therapy Techniques
3.2 Physical Methods of Gene Transfer
3.2.1 Electroporation
3.2.2 Hydrodynamic
3.2.3 Microinjection
3.2.4 Particle Bombardment
3.2.5 Ultrasound-Mediated Transfection
3.3 Vectors for Gene Therapy
3.3.1 Viral Vectors
3.3.2 Non Viral Vectors
4. Industry Overview 4.1 Market Drivers
4.1.1 Failure of Conventional Therapies to Treat Cancers
4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
4.1.4 Growing Interest of Venture Capital Firms 4.2 Market Restraints
4.2.1 Stringent Regulatory Laws & Safety Concerns
4.2.2 Pitfalls in Current Technique
4.2.3 High Cost of the Gene Therapy Drugs 4.3 Market Opportunities
4.3.1 Approval of Gene Therapy Drug in Europe
4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
4.4 Industry Trends 4.4.1 Gene Silencing: Gaining Momentum
4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
4.4.4 Nanotechnology: Empowering Gene Therapy
4.4.5 Gene Therapy: A New Hope to Treat Blindness
4.4.6 Gene Therapy: Potential Cure for Cancer
4.5 Winning Imperatives
4.5.1 Investment in R&D Activities
5. Clinical Trial Assessment & Pipeline Analysis
5.1 Clinical Trials
5.1.1 By Geography
5.1.2 By Indication
5.1.3 By Gene Type
5.1.4 By Vector
5.1.5 By Clinical Trial Phase
5.2 Pipeline Analysis
6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario
6.1 Regulatory Landscape
6.1.1 US 6.1.2 Canada
6.1.3 Europe 6.1.4 Japan
6.1.5 China
6.1.6 India
6.1.7 Australia
6.2 Reimbursement Scenario in Global Market
7. Marketed Gene Therapies
7.1 Neovasculgen
7.2 Glybera
7.3 Gendicine, Rexin-G, Oncorine
7.3.1 Gendicine
7.3.2 Rexin G
7.3.3 Oncorine
8. Global Gene Therapy Market
9. Gene Therapy Market by Application
9.1 Oncology
9.1.1 Clinical Trials
9.1.1 Prevalence
9.1.3 Market Outlook
9.2 Cardiovascular Diseases
9.2.1 Clinical Trials
9.2.2 Prevalence
9.2.3 Market Outlook
9.3 Infectious Diseases
9.3.1 Clinical Trials
9.3.2 Prevalence
9.3.3 Market Outlook
9.4 Neurological Diseases
9.4.1 Clinical Trials
9.4.2 Prevalence
9.4.3 Market Outlook
9.5 Genetic Diseases
9.5.1 Clinical Trials
9.5.2 Prevalence
9.5.3 Market Outlook
9.6 Others
9.6.1 Clinical Trials
9.6.2 Prevalence
9.6.3 Market Outlook
10. Global Gene Therapy Market Size by Geography
10.1 North America
10.2 Europe
10.3 Asia
10.4 Rest of the World (RoW)
11. Competitive Landscape
11.1 Strategies Adopted by Various Players
11.1.1 Strategic Collaborations
11.1.2 Acquisitions
11.1.3 Funding & Investments
11.2 Companies Progress in Gene Therapy In 2015
12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)
12.1 Spark Therapeutics, LLC
12.2 ViroMed Co. Ltd. dba VM BioPharma
12.3 Advantagene Inc.
12.4 Bluebird Bio
12.5 Sanofi
12.6 Vical Inc.
12.7 Oxford BioMedica Plc
12.8 Genethon
12.9 uniQure N.V.
12.10 Human Stem Cells Institute
12.11 Shanghai Sunway Biotech Co. Ltd.
12.12 Sibiono GeneTech Co. Ltd.
For more information visit http://www.researchandmarkets.com/research/5bp8m7/global_gene
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article